Whether reversibility in airway obstruction with 0-adrenergic stimulant is a significant determinant for the outcome was tested in 59 patients with pulmonary emphysema and chronic bronchitis. During four years of follow-up, 43 (73 percent) patients survived and 16 (27 percent) died. Initial VC, FVC, FEV1, and PaOG were significantly smaller, and PaCO2 was significantly larger in nonsurvivors than those in survivors. After orciprenaline sulfate (10 mg in 0.5 ml solution) inhalation, VC and FEVI increased in comparable amount between the two groups. Airway reversibility as Many physiologic and clinical factors determine the prognosis in patients with chronic obstructive pulmonary disease (COPD). Among these, hypoxemia and cor pulmonale seem to be of critical importance.' Spirometric variables such as VC and FEV, are also useful to predict the outcome.23
Many physiologic and clinical factors determine the prognosis in patients with chronic obstructive pulmonary disease (COPD). Among these, hypoxemia and cor pulmonale seem to be of critical importance.' Spirometric variables such as VC and FEV, are also useful to predict the outcome. 23 Bronchoconstriction is one of the major features of bronchial asthma as well as two other categories of COPD, ie, pulmonary emphysema and chronic bronchitis. However, it is not wholly known whether bronchoconstriction or its reversibility is important in modifying the course and prognosis. It is possible that airflow limitation caused by chronic bronchoconstriction is one of the critical factors leading to hypoxemia due to ventilation-perfusion mismatch and cor pulmonale in these patients.
This report has aimed to evaluate the relation between airway response to inhaled 3-adrenergic bronchodilator and prognosis in COPD excluding extrinsic asthma. We believe that the critical analysis of the effect of 3-adrenergic stimulants is important from the prognostic point of view because bronchodilators are widely used in clinical practice.
METHODS
The subjects were 59 patients with pulmonary emphysema and chronic bronchitis selected from our background COPD patients (n=232). They fulfilled the exclusion criteria of extrinsic asthma *From the First Department of Medicine, School estimated by percentage changes in FEV1 before and after the bronchodilator (reversibility index) was similar between the two groups. In the 16 nonsurvivors, hypoxemic patients had similar FEV,, FEV,/FVC, and reversibility indices as normoxemic patients. These results indicate that not airway reversibility per se but a fixed or irreversible component of airway obstruction is one of the determinants of the prognosis in pulmonary emphysema and chronic bronchitis. Chronic hypoxemia is related to neither airway obstruction nor its reversibility, while it does influence the prognosis.
(below). The diagnosis of pulmonary emphysema and chronic bronchitis was made by detailed medical history, complete physical examination, posteroanterior and lateral chest roentgenograms, bronchoalveolography and alveolography (40 patients), and pulmonary function tests (all patients). Minimal criterion for airway obstruction was FEV1/FVC below 70 percent after ,B-adrenergic bronchodilator inhalation. Extrinsic asthmatics, diagnosed by reversible attacks of wheezing, eosinophilia, high serum IgE levels, positive skin tests for allergens, a family history of asthma and allergic diseases within second degree relatives, were excluded from the study. Patients whose FEV,/FVC is below 25 percent, FEV, below 20 percent of predicted value, PaO2 below 45 mm Hg, and PaCO2 above 70 mm Hg were excluded because they were too disabled to obtain reliable pulmonary function data.
Clinical types of COPD were classified according to the criteria utilizing daily sputum production, Dco/VA and TLC.4 Briefly, emphysema was assumed to be predominant when daily sputum amount was less than 10 ml, TLC was more than 120 percent of predicted value, and Dco/VA was less than 1. 5. These characteristics were assigned as minus values. The opposite characteristics for the three criteria that gave plus value (sputum amount more than 10 ml/24 h, TLC less than 105 percent of predicted value, and Dco/VA more than 3) were used for categorizing bronchitis patients. The patients with zero point were assumed to be intermediate. measurements in the sitting position, and arterial blood gas and pH measurements in the supine position.
After the initial hospitalization, the patients were treated either in the outpatient clinic or the ward with a standard therapeutic regimen for COPD, ie, oral bronchodilators. antitussives. mucolytics, and occasional antibiotics, corticosteroids, and diuretics when necessary. Inhaled bronchodilators were not used as a routine treatment. Digitalization was seldom required during acute exacerbation and cor pulmonale. Domiciliary oxygen therapy was not performed in all the patients. After four years from the inhalation test, a questionnaire was sent to patients to determine the cause and the date of death if it had L 2r5 FIGURE 1. Changes in spirometric variables after orciprenaline inhalation. The VC and FEV, increased significantly in both survivors and nonsurvivors (p<0.05). Vertical bars denote standard errors. occurred. A COPD death was considered to be a cause of death only ifdeath was due to respiratory failure or cor pulmonale (confirmed by the medical records).
Comparisons (Fig 1) . Individual reversibility indices in the two groups are shown in Figure 2 . Mean values were 8± SD 11 percent in survivors and 13±11 percent in nonsurvivors (NS).
The occurrence rates of high responders to orciprenaline inhalation (patients with a reversibility index higher than 20 percent) were similar between survivors and nonsurvivors (21 and 25 percent, respectively, NS).
The patients wvere reclassified into two groups ac- The course and prognosis ofpulmonary emphysema and chronic bronchitis is hardly modified by conventional treatment regimens except by long term oxygen therapy.89 An American-Canadian cooperative study showed that IPPB therapy per se does not modify outcome, rate, and duration of hospitalizations, change in lung function, and life quality compared to compressor nebulizer therapy.'0 However, whether bronchodilator therapy is advantageous to improve the life expectancy was not systematically analyzed in this study. In this connection, it may be useftil to examine whether or not airway reversibility with bronchodilators is related to the course and prognosis in COPD patients.
Among many prognostic factors, sex, age, clinical types of COPD, nutrition, lung function derangement, frequency of cor pulmonale, history of childhood airway infection, episodes of acute exacerbation, smoking habits, and socioeconomic status are listed to be critical in determining the outcome of COPD patients.' Previous reports were based on data obtained from patients with chronic airflow limitation including bronchial asthma and "astlhmatic" bronchitis. With advances in diagnostic procedures, patients with extrinsic asthma may be differentiated clearly from the other two categories of COPD, ie, pulmonary emphysema and chronic bronchitis. After excluding extrinsic asthma, our study has demonstrated a similar prognosis between patients with better airway reversibility and those with lesser improvement. However, the relatively small number of patients studied may limit our conclusion.
The death rate of the patients in this study was 27 percent at four years which miglht be lower than those reported in the other studies ofpatients with COPD. Fig 3) .
According to the report of Barter and FEV,/FVC) and reversibility index.
Airway reactivity to f-adrenergic stimulant has been reported to be one of the critical factors determining prognosis of patients with airflow limitation. However, there is some controversy among the reports. In two prognostic studies, larger airway reversibility was correlated with larger yearly decline in FEV1.',2' In another report, the percentage increase in FEV1 after isoproterenol inhalation was documented to be the best discriminator for showing the outcome ofpatients with COPD.6 These facts may designate that FEV1 after bronchodilator inhalation can be a predictor for the prognosis. In the report of Postma et al,3 patients with larger FEV1 after bronchodilator inhalation had a better prognosis. Based on this, they thought that longterm bronchodilator therapy is beneficial for patients with airway obstruction. However, "asthmatic" bronchitis was included in their patients, which may modify their results.
Our findings have an important bearing on treatment policy. COPD seems to be an ever progressing disorder whose course and prognosis are little improved by conventional treatment regimens except by long-term oxygen therapy.89 Our failure to find a difference in airway reversibility with inhaled ,B-adrenergic stimulant between patients with a poor outcome and those with a good prognosis may suggest little beneficial effect of the aerosolized bronchodilator therapy. However, we have focused only on the importance of airway reversibility in late to terminal stages of COPD, thus neglecting changes in airway reversibility at earlier stages. This point along with the relatively small number of patients studied may limit our interpretation.
